What Is PT-141? A Research Overview of Bremelanotide and the Melanocortin Peptide Class

PT-141 bremelanotide melanocortin peptide research Durham Peptides Canada

PT-141 (also known as bremelanotide) is a synthetic peptide that has accumulated a substantive published research literature in a distinct corner of the peptide field — the melanocortin receptor system. Unlike the metabolic peptides that dominate current research conversations, PT-141 works through a receptor pathway that connects to skin pigmentation biology, neural signaling, and several other research areas that don't overlap with the GLP-1/GIP/glucagon axis.

This article provides a research-focused overview of PT-141 — its origins, the melanocortin receptor biology that defines its mechanism, the published research history, and the Canadian regulatory context for the broader melanocortin peptide category.

Note: PT-141 is not currently in the Durham Peptides catalog. This article is

informational coverage of published research literature for Canadian researchers following the broader peptide field. The current Durham Peptides catalog includes BPC-157, TB-500, GHK-Cu, MOTS-c, semaglutide, tirzepatide, and retatrutide.

The Origins: From Melanotan to PT-141

PT-141's research history begins with an entirely different research goal. In the 1960s and 1970s, researchers studying skin pigmentation and the natural hormone alpha-melanocyte-stimulating hormone (α-MSH) developed synthetic analogs designed to mimic the hormone's effects on melanin production. The original research compound — Melanotan I — was investigated for its effects on skin pigmentation in research populations.

A second-generation compound, Melanotan II, followed with broader receptor activity. During research on Melanotan II, scientists observed effects beyond the skin pigmentation that was the original research target. These observations prompted further research into a metabolite of Melanotan II — which became known as PT-141, or bremelanotide.

The progression from Melanotan I → Melanotan II → PT-141 illustrates a common pattern in peptide research: a compound studied for one biological effect produces unexpected observations that prompt research into related but distinct mechanisms.

The Melanocortin Receptor System

To understand PT-141, it helps to understand the melanocortin receptor system — a family of five related receptors (MC1R through MC5R) that respond to melanocortin peptides like α-MSH. Each receptor has different tissue distributions and functions:

MC1R. Located primarily in skin melanocytes (pigment-producing cells). Activation stimulates melanin production. The receptor most associated with the original Melanotan research goals.

MC2R. Located primarily in the adrenal cortex. Responds to adrenocorticotropic hormone (ACTH) and is involved in steroid hormone production.

MC3R and MC4R. Located primarily in the central nervous system. Involved in energy balance, food intake, and various neural signaling pathways. MC4R has been the subject of substantial research in metabolic and neural contexts.

MC5R. Located in various peripheral tissues. Functions less well-characterized than other receptors in the family.

PT-141's research mechanism centers on activity at MC3R and MC4R — the neural melanocortin receptors. This distinguishes it from the original Melanotan compounds, which had broader activity across the receptor family including the skin-localized MC1R.

PT-141 Research Mechanism

The published research literature on PT-141 has investigated its activity at MC3R and MC4R receptors. Key features of the mechanism:

Receptor selectivity. PT-141 shows preferential activity at MC3R and MC4R compared to MC1R, distinguishing its research profile from the broader-activity Melanotan compounds.

Central nervous system activity. Because MC3R and MC4R are concentrated in the brain, PT-141 has been investigated for effects mediated through neural rather than peripheral tissue mechanisms.

Pharmacokinetic profile. PT-141 has a short half-life by design, producing relatively brief receptor activation rather than sustained exposure. For more on why short half-lives can be biologically appropriate, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days.

Manufacturing. PT-141 is produced via Solid-Phase Peptide Synthesis (SPPS), the modern standard for research peptide manufacturing. See Vegan Peptides: Why It Matters and How Synthetic Manufacturing Changed Everything.

Research History and Published Literature

PT-141 has been studied in published research literature since the early 2000s. The research base includes:

Preclinical mechanism studies characterizing receptor binding, pharmacokinetics, and biological responses across various model systems.

Clinical research in human research populations, with the compound progressing through clinical trial phases for specific indications.

Regulatory developments. PT-141 (under the bremelanotide trade name in pharmaceutical formulations) achieved regulatory approval in some jurisdictions for specific approved indications. The pharmaceutical formulations are separate products in a separate regulatory category from research-use peptide formulations.

Receptor pharmacology studies examining the broader melanocortin receptor system and the implications of MC3R/MC4R activity for various research questions.

The Broader Melanocortin Peptide Class

PT-141 sits within a broader research category of melanocortin-related peptides:

α-MSH (alpha-melanocyte-stimulating hormone). The natural endogenous hormone in the melanocortin system. Foundational for understanding melanocortin biology.

Melanotan I. The first-generation synthetic analog, studied for skin pigmentation effects.

Melanotan II. Second-generation analog with broader receptor activity than Melanotan I.

PT-141 (bremelanotide). Metabolite-derived compound with preferential MC3R/MC4R activity.

Other melanocortin research compounds. The broader research field includes various other melanocortin receptor analogs at different stages of development.

For the foundational concepts on how peptides work in biological systems, see What Are Peptides? A Beginner's Guide to Understanding Peptide Research.

How PT-141 Differs From Other Research Peptide Categories

The melanocortin peptide category is distinct from other peptide research areas:

Different from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptors (GLP-1, GIP, glucagon). The melanocortin receptor system is entirely separate.

Different from tissue-repair peptides. BPC-157 and TB-500 work through tissue-localized angiogenic and cell migration pathways. PT-141's central nervous system activity is a different mechanism.

Different from anti-aging peptides. GHK-Cu and MOTS-c work through gene expression modulation and mitochondrial pathways respectively. Different mechanism families.

Different from growth hormone peptides. Sermorelin, CJC-1295, and ipamorelin work through the hypothalamic-pituitary growth hormone axis. The melanocortin system overlaps slightly with the broader hypothalamic regulatory network but operates through distinct receptor pathways. See Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides.

Regulatory Status in Canada

PT-141 in pharmaceutical formulations (bremelanotide) has achieved regulatory approval in some jurisdictions for specific approved indications. These pharmaceutical products are in a separate regulatory category from research-use peptides.

PT-141 as a research peptide is sold by some research peptide suppliers under research-use-only framing. The compound is not approved by Health Canada as a research peptide product. The standard Canadian research peptide framework applies — research-use-only, laboratory and research applications, not for human or veterinary therapeutic use.

For the broader Canadian regulatory framework, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws.

PT-141 is not currently in the Durham Peptides catalog. Researchers seeking PT-141 for research applications would need to evaluate other suppliers using the standard six-criteria framework — Janoshik-verified third-party testing, ≥99% HPLC purity with mass spectrometry identity confirmation, SPPS synthetic manufacturing, transparent Canadian-dollar pricing, Canadian domestic shipping, and clear research-use-only framing. See 5 Things to Look for in a Canadian Peptide Supplier and Peptides for Sale in Canada: A Researcher's Supplier Directory.

Quality Control Considerations

For any PT-141 research, the standard quality control framework applies:

Identity verification. Mass spectrometry should confirm that the compound matches PT-141's expected molecular weight, distinguishing it from related melanocortin peptides like Melanotan I or Melanotan II. For more on identity verification, see How to Read a Janoshik COA: HPLC, Mass Spec, and the Unique Key Explained.

Purity verification. ≥99% HPLC purity is the research-grade standard. Some impurities in melanocortin peptides may be related sequences or truncated fragments, which would alter pharmacological behavior.

Storage. PT-141, like other lyophilized research peptides, requires standard refrigerated or frozen storage. Reconstituted with bacteriostatic water, shelf life is approximately 28 days under refrigeration. See Peptide Storage & Shelf Life: How to Store BPC-157, Tirzepatide, and Other Research Peptides.

The Research Position of Melanocortin Peptides

The melanocortin peptide research field occupies a smaller corner of the broader peptide research landscape compared to the metabolic peptide categories that dominate current attention. Several factors:

Smaller published research volume compared to GLP-1 receptor agonist research, though substantial in absolute terms.

Distinct mechanism from the metabolic and tissue-repair categories, requiring researchers to understand a separate receptor system.

Specialized regulatory pathway with some pharmaceutical formulations approved in specific jurisdictions while research-use formulations operate in the broader research peptide regulatory framework.

Continued research interest in the melanocortin receptor system as the broader understanding of these neural pathways continues to develop.

Frequently Asked Questions

What is PT-141? A synthetic peptide (also known as bremelanotide) that acts at melanocortin receptors, particularly MC3R and MC4R. Originated from research on melanocortin peptides starting from α-MSH and the Melanotan compounds.

Is PT-141 the same as bremelanotide? PT-141 and bremelanotide refer to the same peptide compound. "Bremelanotide" is the international nonproprietary name; "PT-141" is a research code name commonly used in the research peptide field.

Is PT-141 the same as Melanotan? No. Melanotan I and Melanotan II are earlier melanocortin peptides with broader receptor activity (including MC1R). PT-141 has preferential activity at MC3R and MC4R.

Does Durham Peptides sell PT-141? No. PT-141 is not currently in the Durham Peptides catalog. This article is informational coverage of published research literature.

What's the melanocortin receptor system? A family of five related receptors (MC1R through MC5R) that respond to melanocortin peptides like α-MSH. Different receptors have different tissue distributions and biological roles.

Is PT-141 FDA-approved? PT-141 (under the bremelanotide name) has achieved regulatory approval in some jurisdictions for specific pharmaceutical indications. These pharmaceutical formulations are separate from research-use formulations sold by research peptide suppliers.

Is PT-141 approved in Canada? The Canadian regulatory status differs depending on the formulation. Pharmaceutical formulations operate under their own regulatory pathway. Research-use formulations are not approved by Health Canada as research peptide products and are sold under research-use-only framing.

What's PT-141's half-life? Short — designed to produce brief receptor activation rather than sustained exposure. See Peptide Half-Life Explained.

How is PT-141 manufactured? Solid-Phase Peptide Synthesis (SPPS) — the modern standard for research peptide manufacturing using synthetic amino acids. See Vegan Peptides.

Where does PT-141 fit in the peptide research field? In the melanocortin peptide category — a distinct research area separate from metabolic peptides, tissue-repair peptides, anti-aging peptides, or growth hormone peptides.

Can I buy PT-141 in Canada? PT-141 is not currently in the Durham Peptides catalog. Researchers interested in this compound should evaluate available suppliers using the standard six-criteria framework — see Peptides for Sale in Canada.

Is PT-141 vegan? Yes, when manufactured via Solid-Phase Peptide Synthesis with synthetic amino acids — the modern standard. See Vegan Peptides: Why It Matters.

Final Thoughts

PT-141 represents a distinct corner of the peptide research field — the melanocortin receptor system, with mechanisms separate from the metabolic, tissue-repair, anti-aging, and growth hormone peptide categories. The compound has accumulated a substantive published research literature since the early 2000s, with regulatory developments in some jurisdictions and ongoing research interest.

For Canadian researchers following the broader peptide research field, PT-141 and the melanocortin peptide category warrant attention as part of the broader landscape, even though the compound is not currently in the Durham Peptides catalog.

Durham Peptides' current catalog focuses on the metabolic peptide category (semaglutide, tirzepatide, retatrutide), tissue-repair peptides (BPC-157, TB-500), anti-aging peptides (GHK-Cu, MOTS-c), and combination formulations (Wolverine Stack, GLOW Blend) — see the complete catalog at durhampeptides.ca/category/all-products.

For continued reading on the broader peptide research field, see Peptide Research Trends 2026: What's Emerging in the Field, The Complete Peptide Glossary, and The Canadian Peptide Market in 2026: What Researchers Should Know.

Selected Research References

1. Hadley ME. Discovery That a Melanocortin Regulates Sexual Functions in Male and Female Humans. Peptides. 2005;26(10):1687-1689. https://pubmed.ncbi.nlm.nih.gov/16129509/

2. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies with Melanotan II. International Journal of Impotence Research. 2000;12 Suppl 4:S74-S79. https://pubmed.ncbi.nlm.nih.gov/11035391/

3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. https://pubmed.ncbi.nlm.nih.gov/12851303/

4. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective Facilitation of Sexual Solicitation in the Female Rat by a Melanocortin Receptor Agonist. Proceedings of the National Academy of Sciences. 2004;101(27):10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/

5. Cone RD. Studies on the Physiological Functions of the Melanocortin System. Endocrine Reviews. 2006;27(7):736-749. https://pubmed.ncbi.nlm.nih.gov/17077189/

6. Catania A, Gatti S, Colombo G, Lipton JM. Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. Pharmacological Reviews. 2004;56(1):1-29. https://pubmed.ncbi.nlm.nih.gov/15001661/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational coverage of published research literature on a compound not currently stocked by Durham Peptides. Readers seeking medical guidance should consult a licensed healthcare provider.